Oncology
Clinical program advancement represents key milestone for Aulos as a clinical-stage company and AU-007’s potential as a novel cancer treatment Excerpt from the Press Release: LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced it has dosed the first patient in a…
Read More
Strategic Expansion of Turning Point Precision Oncology Portfolio TPX-4589 (LM-302) Currently in Two Ongoing Phase 1 Studies Agreement Includes Potential Broader Scope to Collaborate on up to Three Additional ADC Programs Excerpt from the Press Release: SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company…
Read More
Findings point to potential new therapeutic targets for this highly aggressive, drug-resistant breast cancer subtype Excerpt from the Press Release: In breakthrough research at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute, scientists have discovered that a protein secreted by tumor cells can switch off the body’s natural defenses against triple negative breast cancer (TNBC).…
Read More
Excerpt from the Press Release: Quantum Leap Healthcare Collaborative™ (Quantum Leap) and Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the selection of Ambrx’s antibody drug conjugate (ADC) ARX788 for a new investigational treatment arm in the I-SPY 2.2…
Read More
New kit enhances menu of FFPE solutions and allows oncology researchers to extract higher yields of concentrated DNA compared to traditional techniques Excerpt from the Press Release: PLEASANTON, Calif.–(BUSINESS WIRE)–Purigen Biosystems, Inc., a leading provider of next-generation technologies for extracting and purifying nucleic acids from biological samples, today announced the launch of the Ionic Cells…
Read More
IO-106 is the third development candidate arising from Immune-Onc’s pioneering pipeline of myeloid checkpoint inhibitors, a new class of immunotherapy that aims to overcome immune resistance in cancer The Company will present a scientific poster at the Society for Immunotherapy of Cancer (SITC) Tumor Immune Microenvironment: A Holistic Approach Workshop Excerpt from the Press Release:…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has been recognized by the Boston Business Journal as one of the Best Places to Work for the second year in a row. Surface was among…
Read More
XL114 is a CARD11-BCL10-MALT1 pathway inhibitor with demonstrated activity in lymphoma models that are resistant to Bruton’s tyrosine kinase inhibitors – Excerpt from the Press Release: ALAMEDA, Calif.–(BUSINESS WIRE)–Apr. 14, 2022– Exelixis, Inc. (Nasdaq: EXEL) today announced initiation of the dose-escalation stage of the first-in-human phase 1 trial of XL114, a novel anti-cancer compound that inhibits the…
Read More
Overall response rate (ORR) of 43% and median duration of response of 6 months seen with navicixizumab-paclitaxel combination in heavily pretreated platinum-resistant ovarian cancer patients Xerna™ TME Panel shows enhanced response in biomarker positive (62%) vs. biomarker negative patients (25%) Results support co-development of navicixizumab and Xerna TME Panel in ovarian cancer Excerpt from the…
Read More
Excerpt from the Press Release: SAN FRANCISCO and SUZHOU, China, April 13, 2022 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy…
Read More